Profiles

Stacey McCarthy

Accounting Administrator

TRAININGS & QUALIFICATIONS

  • GCP CITI: current certificate holder
  • IATA: computer training; current certificate holder
  • Vitals: include temperature (oral, auricle, and temporal), weight, height, blood pressure (manual & automatic), heart rate; site training; (2 yrs)
  • Training for unblinded pharmacist for Alder Migraine study; sponsor & site (2 yrs)
  • Sage 202: SIV Slideshow self-training for Blinded Pharmacist on 22 March 2017
  • Credo 2, 3 and 4: SIV Slideshow self-training for Blinded Pharmacist on 22 May 2016

CLINICAL RESEARCH

  • A randomized, open-label, parallel group real world pragmatic trial to assess the clinical and health outcomes of Toujeo® compared to commercially available basal insulins for initiation of therapy in insulin naïve patients with uncontrolled type 2 diabetes mellitus. Toujeo (LPS14347)
  • To assess Warfarin Management Issues Faced by Atrial Fibrillation Patients in Ambulatory Settings. Elite (CV185-161)
  • A randomized, double-blind, parallel-group, placebo-and-active-controlled, Multicenter Pahse III Study of the efficacy and safety of Olokizumab in Subjects with moderately to severely Active Rheumatoid Arthritis inadequately controlled by Methotrexate Therapy. CREDO 2 (CL04041023)
  • A randomized, double-blind, parallel-group, placebo controlled, Multicenter Phase III study of the efficacy and safety of Olokizumab in Subjects with moderately to severely Active Rheumatoid Arthritis inadequately controlled by Tumor Necrosis Factor Alpha (TNF-a) Inhibitor Therapy. CREDO 3 (CL04041025)
  • A Mulit-center, open-label, Phase 3 study of the efficacy and safety of Olokizumab in Subjects with moderately to severely active Rheumatoid Arthritis.  CREDO 4 (CL04041024)
  • A multi-center, randomized, double-blind, parallel-group, placebo-controlled study evaluating the efficacy, safety and pharmacokinetics of SAGE-547-PPD-202 injection in the treatment of adult female subjects with severe postpartum depression and adult female subjects with moderate postpartum depression.  SAGE-547-PPD-202